Sign in to view content

One Year Follow-Up in a Phase ½ Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa

Benjamin Bakall, MD, PhD

Video
Published 2024

Related

BVA Analysis of Low- or High-Dose MCO-010 Optogenetics Therapy for Retinitis Pigmentosa: First Time 100-Week TOPLINE Results From a Phase 2b/3 Clinical trial (RESTORE)
Michael A. Singer, MD
Updates from the Field
2024
AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 6-month Results From a Phase 1/2 Clinical Trial
Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS
Updates from the Field
2020
Safety and Activity of a Single, Intravitreal Injection of Human Retinal Progenitor Cells for Treatment of Retinitis Pigmentosa (RP)
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2018

Category: Hereditary Retinal Disease & Genetics

See more